Psychiatric treatment – Page 3

Are Side Effects Necessary for Antidepressive Treatment: The Psilocybin Experience

mycolabadmin

Researchers are studying psilocybin (a compound from certain mushrooms) as a potential treatment for depression. However, there is debate about whether the hallucinogenic side effects are necessary for its therapeutic benefits. This paper argues that new research suggests the antidepressant effects work through specific brain pathways (serotonin, opioid, and glutamate systems) that don’t require hallucinations. The author suggests developing safer, non-hallucinogenic antidepressants that maintain the same therapeutic benefits.

Psilocybin therapy and anorexia nervosa: a narrative review of safety considerations for researchers and clinicians

mycolabadmin

This review examines the safety of psilocybin therapy for treating anorexia nervosa, a serious eating disorder with limited treatment options. The authors analyze how psilocybin’s common side effects (like increased heart rate, nausea, and dizziness) interact with medical complications already present in people with anorexia. Based on early clinical trials, they conclude that psilocybin can be safely used in this population with proper medical screening and monitoring protocols tailored to their specific vulnerabilities.

Current situation regarding psychedelics and magic mushroom in Korea

mycolabadmin

This article reviews the current status of psychedelic mushrooms and their potential medical uses in Korea. Several wild mushroom species containing psilocybin have been identified in Korea and can cause hallucinations and other nervous system effects lasting a few hours. While psychedelics show promise for treating depression and anxiety, Korea currently classifies them as controlled substances, and only approved clinical trials can be conducted with government permission.

Body mass index (BMI) does not predict responses to psilocybin

mycolabadmin

Researchers investigated whether a person’s body weight affects how they respond to psilocybin-assisted therapy. Analyzing 77 participants across three studies, they found that BMI did not predict how intensely people experienced the drug or how much their mental health improved afterward. This surprising finding suggests that everyone might benefit from the same fixed dose of psilocybin rather than doses adjusted to body weight, making therapy simpler and more cost-effective to deliver at scale.

Safety, tolerability, and clinical and neural effects of single-dose psilocybin in obsessive–compulsive disorder: protocol for a randomized, double-blind, placebo-controlled, non-crossover trial

mycolabadmin

This study tests whether psilocybin (the active compound in certain mushrooms) can help people with obsessive-compulsive disorder who haven’t responded to standard treatments. In a carefully controlled trial, participants receive either a single dose of psilocybin or a placebo while receiving psychological support, with their brain activity and symptoms monitored. The research aims to determine if this novel treatment is safe and whether it could work faster than existing medications for this difficult-to-treat condition.

Ketamine, Psychedelics, and Psychotherapy: Reframing, Redefining, Renaming Treatment Models

mycolabadmin

This paper addresses confusion about how ketamine and psychedelics are being used to treat mental health conditions like depression and PTSD. The authors propose new clear definitions to distinguish whether these drugs are used alone for their chemical effects, combined with established talk therapies, or used to create experiences that are then processed in therapy. Using these clearer definitions will help patients, doctors, and regulators better understand what treatments involve and make more informed decisions.

We need to talk about shrooms

mycolabadmin

The article discusses how psychedelic mushrooms have transformed from being seen as dangerous drugs in the 1960s to being studied as potential psychiatric treatments today. While research shows promise for treating depression, trauma, and addiction, the author warns against oversimplified narratives that ignore important context about how these experiences work and potential risks. The piece calls for careful, balanced discussion about psychedelics that considers both benefits and concerns.

Pharmacokinetics of Psilocybin: A Systematic Review

mycolabadmin

This review examines how the body processes psilocybin, a compound from magic mushrooms being studied for treating depression and anxiety. When taken orally, psilocybin is quickly converted to its active form, psilocin, which reaches peak levels in the bloodstream within 1-4 hours and is eliminated mainly through urine. The body’s ability to process psilocybin involves specific liver enzymes that vary between individuals, potentially explaining why people respond differently to the same dose and why certain medications can interfere with its effects.

Psychedelic-assisted psychotherapy: The need to monitor adverse events

mycolabadmin

While psychedelics show promise for treating depression and other mental health conditions, researchers need better systems to monitor and report any harmful effects they might cause. This paper calls for more careful, consistent tracking of both physical changes (like blood pressure) and psychological experiences during psychedelic therapy. The authors emphasize that safety monitoring should continue even after patients leave the clinic and that women may experience different side effects than men.

Further education in psychedelic-assisted therapy – experiences from Switzerland

mycolabadmin

As psychedelic drugs show promise in treating serious mental health conditions like depression and PTSD, there is growing need to train therapists to safely administer these novel treatments. Switzerland’s leading medical association has developed a comprehensive three-year training program that combines classroom learning with hands-on practice to prepare doctors and psychologists. The program faces overwhelming demand, with far more people wanting to train than available spots, highlighting the urgent need for more specialized education programs as these treatments potentially become mainstream medications.

Research Topic: Psychiatric treatment